TMS Targeting Methods for Depression

(XRnav Trial)

Overseen By Christoph Leuze, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Stanford University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a special headset that combines real and virtual elements to help doctors place a magnetic coil on the head more accurately during TMS treatment for depression. The goal is to see if this method improves treatment outcomes compared to traditional methods. Transcranial magnetic stimulation (TMS) is a relatively new technique used to treat depression by delivering magnetic radiation to the head using a hand-held coil.

Research Team

Jennifer A McNab, PhD

Principal Investigator

Stanford University

Eligibility Criteria

This trial is for adults aged 18-75 with treatment-resistant depression who are prescribed transcranial magnetic stimulation (TMS) therapy. They must be MRI-compatible, meaning no metal in the body and able to complete screening at specific centers. Excluded are those with neurological disorders, pacemakers or certain implants, and a history of substance abuse.

Inclusion Criteria

I have depression that hasn't improved with standard treatments and am prescribed rTMS.

MRI scanning eligibility, including no evidence of any form of metal embedded in the body

Healthy subjects with no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs

Exclusion Criteria

Any contraindication to being scanned in the 3.0T scanner at the Lucas Center or CNI such as having a pacemaker or implanted device that has not been cleared for scanning at 3.0 Tesla

I have no history of major neurological disorders or brain-related treatments.

Treatment Details

Interventions

• Mixed reality neuronavigation (Device)
• Transcranial Magnetic Simulation (Device)

Trial Overview The study tests if using mixed reality devices can improve TMS targeting for treating depression compared to traditional scalp measurements or commercial neuronavigation systems. It aims to see if this method reduces setup time and is practical in clinical settings.

Participant Groups

Group I: No neuronavigation Active Control 1 Intervention

For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via scalp measurements.

Group II: Mixed reality neuronavigation Active Control 2 Interventions

For this group, the stimulation location for repetitive transcranial stimulation treatment is estimated by the clinician via a mixed reality neuronavigation device.

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+